PER-011-01已完成未知
EFFICACY AND SAFETY OF 200 MCG OR 400 MCG OF MOMETHASONE FUROATE IN NASAL OR PLACEBO AEROSOL FOR THE TREATMENT OF NASAL POLIES IN SUBJECTS OF 18 YEARS OF AGE IN ADVANCE
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •The subjects must have a diagnosis of bilateral nasal polyps in both the Selection Visit and the Start Visit. The nasal polyps on each side (left and right) should be Grade 1, 2 or 3.
- •Subjects must present clinically significant nasal congestion / obstruction, with an instant morning rating> 2 in each of the last seven days of the two-week selection-start period. Symptoms will be scored once a day in the morning.
- •The subjects must be 18 years of age and older and can be of both sexes and any race.
- •The subjects must have a good state of health and not suffer from any clinically significant disease that could interfere with the study schedule or procedures, or that could compromise the subject´s safety.
- •Subjects must give their consent in writing and be able to comply with dose and visit schedules.
- •Asthmatic subjects who require treatment with inhaled corticosteroids to maintain pulmonary function should follow a dosing regimen that does not exceed 840 mcg of beclomethasone per day, or its equivalent, at least during the entire month before the Selection. Said regime must remain stable throughout the course of the study.
排除标准
- •Women who can conceive and who are not using medically acceptable methods of contraception.
- •Women who are pregnant or breastfeeding.
- •Subjects with a history of allergic rhinitis in the last two years.
- •Subjects who have undergone nasal or sinus surgery in the last 6 months.
- •Subjects with presumed fibrotic nasal polyposis.
- •Subjects who have undergone three or more nasal surgeries.
- •Subjects who have undergone ethmoidectomies.
- •Subjects with complete nasal obstruction (Grade 4 nasal polyposis).
- •Subjects with non-stabilized asthma requiring administration of inhaled corticosteroids at doses of 840 mcg / day of beclomethasone (or its equivalent). Asthmatic subjects will be excluded if the FEV1 is less than 70% of the predicted and if they have a history of asthma attacks that could have been fatal.
- •Subjects who present current sinusitis or concurrent nasal infection, or who have had a nasal infection in the two weeks prior to the Screening Visit.
- •Subjects with rhinitis medicamentosa.
- •Subjects with Churg-Strauss syndrome (vasculitis, asthma, fever and eosinophilia).
- •Subjects with Young´s syndrome (sinus-pulmonary infections and obstructive azoospermia).
- •Subjects that present any clinically relevant abnormal result in the vital signs of the Selection or the Start, or any clinically significant abnormal result in the electrocardiograms.
- •Subjects who have received some treatment with intranasal steroids in the two weeks before the Selection.
- •Subjects who have used a research drug in the 30 days prior to Visit 1.
- •Immunocompromised subjects, with cystic fibrosis, primary ciliary dysfunction or Kartagener syndrome (immobile cilia), glaucoma or a history of posterior subcapsular cataract, or clinically significant cardiovascular, pulmonary, renal, hepatic, metabolic, hematologic or neurological diseases that, at the discretion of the Researcher, may interfere with the evaluation of the therapy.
- •Subjects hypersensitive to corticosteroids, or allergic to more than two kinds of medications.
- •Subjects that have not complied with the depuration periods of the medications, established in the protocol, before Visit 1.
- •Subjects who present upper respiratory tract infection at present or who have had an upper respiratory tract infection in the two weeks prior to the Screening Visit.
- •Subjects with deviation of the nasal septum that requires corrective surgery.
- •Subjects with perforation of the nasal septum.
- •Members of the study staff, or subjects related to a member of the staff of the center who intervenes directly in the study.
研究者
相似试验
未知
不适用
EFFICACY AND SAFETY OF 200 MCG OR 400 MCG OF MOMETHASONE FUROATE NASAL SPRAY OR PLACEBO IN THE TREATMENT OF ACUTE SINUSITIS EPISODES-J01J01PER-012-01SCHERING PLOUGH RESEARCH INSTITUTE,
已完成
不适用
200µg versus 400µg sublingual misoprostol in prevention of postpartum haemorrhagePregnancy and ChildbirthPOSTPARTUM HAEMORRHAGEPACTR201505001107182Dr I.A Ugwu
已完成
4 期
Efficacy and Safety assessment of Miglitol and Metformin SR Fixed dose combination (MIGNAR MF) in patients of Type 2 Diabetes mellitusCTRI/2012/01/002336Glenmark Pharmaceuticals Limited500
招募中
4 期
Type II Diabetic STUDYCTRI/2016/01/006486SV Limited270
招募中
3 期
Comparing the efficacy of a combination of Mometasone and Olopatadine sprays versus Mometasone spray in children with allergic rhinitisIRCT20150426021944N5Oroumia University of Medical Sciences80